12:00 AM
 | 
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Integrilin eptifibatide: Phase II data; marketed to treat unstable angina and non-Q-wave myocardial infarction and as an adjunct to coronary angioplasty

In CORR and partner Schering-Plough Corp.'s 340-patient Phase II INTRO-AMI study, the combination of Integrilin and half the normal dose of Genentech Inc.'s Activase alteplase tPA restored normal blood flow...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >